HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant

BACKGROUND: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab bindin...

Full description

Saved in:
Bibliographic Details
Published in:Gynecol Oncol
Main Authors: Growdon, Whitfield B., Groeneweg, Jolijn, Byron, Virginia, DiGloria, Celeste, Borger, Darrell R., Tambouret, Rosemary, Foster, Rosemary, Chenna, Ahmed, Sperinde, Jeff, Winslow, John, Rueda, Bo R.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4380649/
https://ncbi.nlm.nih.gov/pubmed/25602714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.01.533
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items